Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus

Current Opinion in Rheumatology

Volumn 9, Issue 5, 1997, Pages 400-409

  Werth, Victoria P ^a   Dutz, Jan P ^a   Sontheimer, Richard D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AUTOANTIBODY; CELL ADHESION MOLECULE; CYTOKINE; SELECTIN; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; GENETIC POLYMORPHISM; HUMAN; HUMORAL IMMUNITY; INFLAMMATORY CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; SKIN LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; ULTRAVIOLET RADIATION;

ANIMALS; ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHOTOBIOLOGY; SKIN;

EID: 0030754711     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199709000-00005     Document Type: Review

References (91)

1. Casciola-Rosen L, Rosen L: Ultraviolet light-induced apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997, 6:175-180. In this state-of-the-art-review, the authors summarize their elegant series of studies that have illuminated a new molecular mechanism by which ultraviolet radiation can perturb the normal intracellular distribution of autoantigens such as Ro/SS-A and how this mechanism might contribute to the induction or exacerbation of autoantibody production.
2. Casciola-Rosen L, Rosen A, Petri M, Schlissel M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1996, 93:1624-1629. The authors study the apoptotic effect of ultraviolate B on HeLa cells and cultured human vascular endothelial cells and document the extracellular display of phosphatidylserine with resultant procoagulant activity. They propose that this exposure of anionic phospholipids may also induce the antiphospholipid antibodies occasionally seen in LE.
3. Utz PJ, Hottelet M, Shur PH, Anderson P: Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997, 185:843-854.
4. Bennion SD, Norris DA: Ultraviolet light modulation of autoantigens, epidermal cytokines and adhesion modecules as contributing factors of the pathogenesis of cutaneous LE. Lupus 1997, 6:181-192. A review of the multiple ways in which ultraviolet light may affect the immune environment and potentiate cutaneous LE. Relevant literature up to 1995 is reviewed and a model of pathogenesis is proposed.
5. Grether-Beck S, Olaizola-Horn S, Schmitt H, Grewe M, Jahnke A, Johnson JP, Brwiba K, Sies H, Krutmann J: Activation of transcription factor AP-2 mediates UVA radiation and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci U S A 1996, 93:14586-14591.
6. Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA: Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol 1990, 94:77-85.
7. Yu H-S, Chinag L-C, Chang CH, Kang JW, Yu CL: The cytotoxic effect of neonatal lupus erythematosus and maternal sera on keratinocyte cultures is complement-dependent and can be augmented by ultraviolet radiation. Br J Dermatol 1996, 135:279-301.
8. Lanzavecchia A: How can cryptic epitopes trigger autoimmunity? J Exp Med 1995, 181:1945-1948.
9. Scofield RH, Henry WE, Kurien BT, James JA, Harley JB: Immunization with short peptides from the sequence of the systemic lupus erythematosus-associated 60-kDa Ro autoantigen results in anti-Ro ribonucleoprotein autoimmunity. J Immunol 1996, 156:4059-4066. Rabbits were immunized with 15- to 18-mer peptides from the sequence of the 60-kD Ro antigen. These peptides were known to be either bound or not bound by human anti-Ro sera. Animals produced antibodies to the immunizing peptides as well as autoimmune responses to serial 8-mer peptides from the entire 60-kD Ro antigen. A proportion of animals developed antibody responses to the La antigen as well. In each case there was evidence of epitope spreading, revealing that immunization with a self-peptide can ultimately result in the processing and successful presentation of a self-protein to T cells.
10. Keech CL, Gordon TP, McCluskey J: The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J Immunol 1996, 157:3694-3699.
11. Lee LA, Frank MB, McCubbin VR, Reichlin M: Autoantibodies of neonatal lupus erythematosus. J Invest Dermatol 1994, 102:963-966.
12. Boutjdir M, Chen L, Zhang ZH, Tseng CE, Didonato F, Rashbaum W, Morris A, El-Sherif N, Buyon JP: Arryhthmogenicity of IgG and anti-52-kD SSA/Ro affinity purified antibodies from mothers of children with congenital heart block. Circ Res 1997, 80:354-362.
13. Zimmermann C, Smolen JS, Graninger W, Petera P, Fabini G, Hassfeld W, Hsfler E, Steiner G: Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestation in patients with systemic lupus erythematosus. J Rheumatol 1996, 23:1897-1903.
14. McCauliffe DP, Faircloth E, Wang L, Hashimoto T, Hoshino Y, Nishikawa T: Similar Ro/SS-A autoantibody epitope and titer responses in annular erythema of Sjögren's syndrome and subacute cutaneous lupus erythematosus. Arch Dermatol 1996, 132:528-531.
15. Miyagawa S, Shinohara K, Fujita T, Kidoguchi K, Fukumoto T, Hashimoto K, Yoshioka A, Shirai T: Neonatal lupus erythematosus: analysis of HLA class II alleles in mothers and siblings from seven Japanese families. J Am Acad Dermatol 1997, 36:186-190.
16. Cheng ST, Nguyen TQ, Yang YS, Capra JD, Sontheimer RD: Calreticulin binds hYRNA and the 52 KD polypeptide component of the Ro/SS-A ribonucleoprotein autoantigen. J Immunol 1996, 156:4484-4491.
17. Lieu TS, Sontheimer RD: A subpopulation of WIL-2 cell calreticulin molecules is associated with Ro/SS-A ribonucleoprotein particles. Lupus 1997, 6:40-47.
18. Nguyen TQ, Capra JD, Sontheimer RD: Calreticulin is transcriptionally upregulated by heat shock, calcium, and heavy metals. Mol Immunol 1996, 33:379-386.
19. Pogue GP, Hofmann J, Duncan R, Best JM, Etherington J, Sontheimer RD, Nakhasi HL: Autoantigens interact with cis-acting elements of rubella virus RNA. J Virol 1996, 70:6269-6277.
20. Kishore U, Sontheimer RD, Sastry KN, Zappi EG, Hughes GRV, Khamashta MA, Reid KBM, Eggleton P: The systemic lupus erythematosus (SLE) disease autoantigen: calreticulin can inhibit C1q-association with immune complexes. Clin Exp Immunol 1997, 108:181-190.
21. Kishore U, Sontheimer RD, Sastry KN, Zaner KS, Zappi EG, Hughes GRV, Khamashta MA, Strong P, Reid KBM, Eggleton P: Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem J 1997, 322:543-554.
22. Furukawa F: Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Lupus 1997, 6:193-202.
23. Cohen PL, Eisenberg RA: Ipr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991, 9:243-269.
24. Peng SL, Madaio MP, Hughes DPM, Crispe IN, Owen MJ, Wen L, Hayday AC, Craft J: Murine lupus in the absence of αβ T cells. J Immunol 1996, 156:4041-4049.
25. Peng SL, Madaio MP, Hayday AC, Craft J: Propagation and regulation of systemic autoimmunity by γδ T cells. J Immunol 1996, 157:5689-5698.
26. Peng SL, Mcniff JM, Madaio MP, Ma J, Owen MJ, Flavell RA, Hayday AC, Craft J: αβ T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol 1996, 158:2464-2470. Lupus-prone MRL/lpr mice were rendered deficient in either CD40 ligand, αβ T cells, or both by mating the MRL/lpr mice with CD40 ligand-deficient mice and T-cell receptor α chain-deficient mice. The autoimmune phenotypes were then analyzed. Skin disease phenotype did not strictly correlate with renal disease, suggesting different pathogenetic mechanisms: CD40 ligand-negative, αβ T-cell receptor-positive mice developed low levels of autoantibodies and mild renal disease yet had unchanged cutaneous disease. CD40 ligand-negative, αβ T-cell receptor-negative animals developed higher levels of anti-double-stranded DNA autoantibodies and developed renal disease yet failed to develop skin disease. Persistence of skin disease in animals singly deficient in αβ T cells or CD40 ligand argues against a solely αβ T cell-dependent autoantibody mechanism. The absence of disease in doubly deficient mice was correlated to the absence of complement-fixing IgG2a isotype.
27. David-Bajar KM, Davis BM: Pathology, immunopathology and immunohistochemistry in cutaneous lupus erythematosus. Lupus 1997, 6:145-157.
28. Furukawa F, Tokura Y, Matsushita K, Iwasaki-Inuzuka K, Onagi-Suzuki K, Yagi H, Wakita H, Takigawa M: Selective expansions of T cells expressing Vbeta8 and Vbeta13 in skin lesions of patients with chronic cutaneous lupus erythematosus. J Dermatol 1996, 23:670-676.
29. June CH, Bluestone LM, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 1994, 15:321-331.
30. Denfeld RW, Dietrich A, Weiss JM, Kind P, Sontheimer RD, Schopf E, Linsley PS, Simon JC: In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Arthritis Rheum 1997, 40:814-821. In situ expression of the B7 and CD28 receptor families was examined in active skin lesions as well as in nonlesional skin of patients with SLE, SCLE, and CCLE and healthy controls using immunocytochemistry and RT-PCR. B7-1 (CD80) and B7-2 (CD86) were found to be expressed on dermal and (minimally) on epidermal antigen-presenting cells and T cells. This compartmentalization was confirmed by comparative RT-PCR of skin biopsy specimens and suction blisters. These cells were able to bind CTLA-4 immunoglobulin in situ. CD28 was expressed by most T cells infiltrating either the dermis or epidermis. Nonlesional skin in subjects and normal controls was negative for these markers.
31. Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ: VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol 1996, 135:678-686.
32. Belmont HM, Buyon J, Giorno R, Abramson S: Upregulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: the Shwartzman phenomenon revisited. Arthritis Rheum 1994, 37:376-383.
33. Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, Yang J, Chang S, Hemati N, Richardson B: Mechanisms of drug-induced lupus. II: T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupus-like disease in syngeneic mice. J Clin Invest 1996, 97:2866-2871. A conalbumin-reactive T-helper 2 T-cell clone was induced to overexpress LFA-1 by transfection and was subsequently shown to lyse autologous macrophages and to induce autoimmunity in congenic mice in the form of anti-DNA responses, immune complex kidney disease, and pulmonary alveolitis. Treatment of the parent clone with procainamide and ensuing DNA hypomethylation resulted in similar LFA-1-dependent autoimmunity. The authors thus propose that DNA hypomethylation-induced LFA-1 overexpression may be sufficient to break tolerance, presumably by enhancing cross-reactive specificities of T cells.
34. Richardson B, Powers D, Hooper F, Yung RL, O'Rourke K: Lymphocyte function-associated antigen 1 overexpression and T cell autoreactivity. Arthritis Rheum 1994, 9:1363-1372.
35. Stein LF, Saed GM, Fivenson DP: T-cell cytokine network in cutaneous lupus erythematosus. J Am Acad Dermatol 1997, 36&37:191-196. To study the local cytokine profile in cutaneous LE, RT-PCR was performed on lesional skin from 19 patients with cutaneous LE (eight with SLE, two with SCLE, and nine with CCLE) and four healthy controls. Analysis of interleukin-2, -4, -5, and -10 and interferon gamma mRNA expression was performed. Interleukin-10 and interferon gamma were found in the majority of specimens, including normal controls. Interleukin-5 was found 15 of 19 LE specimens and in none of the controls. The pattern of cytokine mRNA expression did not vary with different subtypes of cutaneous LE. These results indicate a mixed cytokine pattern possibly favoring cell adhesion via interferon gamma-mediated increases in ICAM-1 expression and a T-helper 2 response with significant interleukin-5 production and detectable interleukin-10 production.
36. Jacob CO, Lee SK, Strassmann G: Mutational analysis of TNF-α gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996, 156:3043-3050. The lupus-prone mouse strain NZW shows a reduced production of TNF-α as does a subset of patients with SLE. This is associated with a polymorphism in a simple tandem repeat sequence within the promoter region of the gene. Using a luciferase reporter system and TNF-α promoter constructs from various mouse strains, the authors show that mutations in the 3′ untranslated region of the TNF-α gene play an important role in the downregulation of TNF-α biosynthesis. Interestingly, although luciferase levels varied, there were no significant differences in luciferase mRNA levels, paralleling a discord in TNF-α protein and mRNA levels seen in these different genetic backgrounds, suggesting that the alteration in the 3′-untranslated region affects primarily posttranslational regulation of protein synthesis.
37. Kim TG, Kim HY, Lee SH, Cho CS, Park SH, Choi HB, Han H, Kim DJ: Systemic lupus erythematosus with nephritis is strongly associated with the TNFβ*2 homozygote in the Korean population. Hum Immunol 1996, 46:10-17.
38. Messer G, Spengler U, Jung MC, Blomer K, Pape GR, Reithmuller G, Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an Ncol polymorphism in the first intron of the human TNF-β gene correlates with a variant amino acid in position 26 and a reduced level of TNF-β production. J Exp Med 173:209-219.
39. Suzuki H, Matsui Y, Kashiwagi H: Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:389-390.
40. Ollier W, Davies E, Snowden N, Alldersea J, Fryer A, Jones P, Strange R: Association of homozygosity for glutathione-S-transferase GSTM1 null alleles with the Ro+/La- autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39:1763-1764.
41. Gilliam JN, Sontheimer RD: Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1982, 4:471-475.
42. Provost TT, Watson R, Simmons-O'Brien E: Significance of the anti-Ro (SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. J Am Acad Dermatol 1996, 35:147-169.
43. Watanabe T, Tsuchida T: Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 1996, 134:123-125.
44. Sanchez NP, Peters MS, Winkelmann RK: The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 1981, 5:673-680.
45. Tuffanelli DL: Lupus erythematosus (panniculitis) profundus: a classic revisited: commentary and report of 22 cases. Hawaii Med J 1982, 41:394-397.
46. Gold SC: An unusual papular eruption associated with lupus erythematosus. Br J Dermatol 1954, 66:429-433.
47. Pandya AG, Sontheimer RD, Cockerell CJ, Takashima A, Piepkom M: Papulonodular mucinosis associated with systemic lupus erythematosus: possible mechanisms of increased glycosaminoglycan accumulation. J Am Acad Dermatol 1995, 32:199-205.
48. Kano Y, Sagawa Y, Yagita A, Nagashima M: Nodular cutaneous lupus mucinosis: report of a case and review of previously reported cases. Cutis 1996, 57:441-444.
49. Kanda N, Tsuchida T, Watanabe T, Tamaki K: Clinical features of systemic lupus erythematosus in men. Dermatology 1996, 193:6-10.
50. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR: Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991, 21:55-64.
51. Yell JA, Mbuagbaw J, Burge SM, Kapadia N, Haroon TS: Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996, 135:355-362.
52. Kapadia N, Haroon TS: Cutaneous manifestations of systemic lupus erythematosus: study from Lahore, Pakistan. Int J Dermatol 1996, 35:408-409.
53. Thornton CM, Eichenfield LF, Shinall EA, Siegfried E, Rabinowitz LG, Lucky AW, Friedlander SF: Cutaneous telangiectases in neonatal lupus erythematosus. J Am Acad Dermatol 1995, 33:19-25.
54. Buyon JP: Neonatal lupus. Curr Opin Rheumatol 1996, 8:485-490.
55. Nitta Y: Lupus erythematosus profundus associated with neonatal lupus erythematosus. Br J Dermatol 1997, 136:112-114.
56. Drenth JP, Vuzevski V, Van Joost T, Casteels-Van Daele M, Vermylen J: Cutaneous pathology in primary erythermalgia. Am J Dermatopathol 1996, 18:30-34.
57. Hostetler L, Werth VP: Cutaneous ulcers in a patient with systemic lupus erythematosus. Arthritis Rheum 1993, 36:91-93.
58. Disdier P, Christides C, Andrac-Meyer L, Rojat-Habib MC, Aillaud MF, Swiader L, Weiller-Merli C, Harle JR, Weiller PJ: L'Anetodermie au cours du syndrome des antiphospholipides. Ann Dermatol Venereol 1996, 123:800-803.
59. Werth VP, Sanchez M, White W, Franks AG: Incidence of alopecia areata in lupus erythematosus. Arch Dermatol 1992, 126:369-371.
60. Fitzgerald EA, Purcell SM, Kantor GR, Goldman HM: Rowell's syndrome: report of a case. J Am Acad Dermatol 1996, 35:801-803.
61. Zalla MJ, Muller SA: The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Suppl (Stockh) 1996, 195:1-15.
62. Snow JL, Su WP: Lipomembranous (membranocystic) fat necrosis: clinicopathologic correlation of 38 cases. Am J Dermatopathol 1996, 18:151-155.
63. Fabre VC, Lear S, Reichlin M, Hodge SJ, Callen JP: Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol 1991, 127:1006-1011.
64. David-Bajar KM, Bennion SD, DeSpain JD, Golitz LE, Lee LA: Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Invest Dermatol 1992, 99:251-257.
65. Magro CM, Crowson AN, Harrist TJ: The use of antibody to C5b-9 in the subclassification of lupus erythematosus. Br J Dermatol 1996, 134:855-862.
66. Lazarova Z, Yancey KB: Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol/L salt-split skin. J Am Acad Dermatol 1996, 35:398-403.
67. Pathak MA: Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. J Dermatol 1996, 23:783-800.
68. Gonzalez E, Gonzalez S: Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996, 35:871-885.
69. Stanford DG, Georgouras KE: Sun protection: SPF versus UPF [letter]. Med J Austr 1996, 164:253-254.
70. Gies HP, Roy CR, Elliott G, Zongli W: Ultraviolet radiation protection factors for clothing. Health Physics 1994, 67:131-139.
71. Feldmann R, Salomon D, Saurat JH, Feldmann R, Salomon D, Saurat JH, Pathak MA: The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1996, 23:783-800.
72. Tsutsui K, Imai T, Hatta N, Sakai H, Takata M, Takehara K: Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996, 35:313-315.
73. Callen JP: Management of antimalarial-refractory cutaneous lupus-erythematosus. Lupus 1997, 6:203-208.
74. Abb J, Abb H, Deinhardt F: Effect of retinoic acid on the spontaneous and interferon-induced activity of human natural killer cells. Int J Cancer 1982, 30:107-110.
75. Rhodes J, Stokes P: Interferon-induced changes in monocyte membrane: Inhibition by retinol and retinoic acid. Immunology 1982, 45:531-536.
76. De Jong EM, Van De Kerkhof PC: Coexistence of palmoplantar lichen planus and lupus erythematosus with response to treatment using acitretin. Br J Dermatol 1996, 134:538-541.
77. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G: Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 1996, 34:244-252.
78. Ashinoff R, Werth VP, Franks AG Jr: Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988, 19:961-965.
79. Aoki T, Ishizawa T, Hozumi Y, Aso K, Kondo S: Chilblain lupus erythematosus of Hutchinson responding to surgical treatment: a report of two patients with anti-Ro/SS-A antibodies. Br J Dermatol 1996, 134:533-537.
80. Nunez M, Boixeda P, Miralles ES, de Misa RF, Ledo A: Pulsed dye laser treatment of telangiectatic chronic erythema of cutaneous lupus erythematosus [letter]. Arch Dermatol 1996, 132:354-355.
81. Abramson AL, Alvi A, Mullooly VM: Clinical exacerbation of systemic lupus erythematosus after photodynamic therapy of laryngotracheal papillomatosis. Lasers Surg Med 1993, 13:677-679.
82. McGrath H Jr, Martinez-Osuna P, Lee FA: Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996, 5:269-274.
83. Knobler RM, Graninger W, Graninger W, Lindmaier A, Trautinger F: Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus: a pilot study. Arthitis Rheum 1992, 35:319-324.
84. McGrath H Jr, Bak E, Zimny ML, Michalski JP: Fluorescent light decreases autoimmunity and improves immunity in B/W mice. J Clin Lab Immunol 1990, 32:113-116.
85. McGrath H Jr, Bak E, Michalski JP: Ultraviolet-A light prolongs survival and improves immune function in (New Zealand black x New Zealand white)F1 hybrid mice. Arthitis Rheum 1987, 30:557-561.
86. Berger CL, Perez M, Laroche L, Edelson R: Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. J Invest Dermatol 1990, 94:52-57.
87. Girardi M, Herreid P, Tigelaar RE: Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. J Invest Dermatol 1995, 104:177-182.
88. Cohen MR, Isenberg DA: Ultraviolet irradiation in systemic lupus erythematosus: friend or foe? Br J Rheum 1997, 35:1002-1007. Good overview of this controversial area relating to ultraviolet light and lupus.
89. Werth VP, Shi X: Distinct effects of ultraviolet A on extracellular matrix gene expression. J Invest Dermatol 1997, 108:625.
90. Klein LR, Elmets CA, Callen JP: Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthitis Rheum 1995, 38:1152-1156.
91. Kind P, Lehmann P, Plewig G: Phototesting in lupus erythematosus. J Invest Dermatol 1993, 100:53S-57S.